High-density lipoprotein/apolipoprotein A-I infusion therapy.

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Atherosclerosis progression is a significant health concern, with high-density lipoprotein (HDL) and apolipoprotein A1 (apoA-I) offering protective effects.
• Previous attempts to increase HDL via oral agents, like torcetrapib, yielded disappointing results due to adverse effects.
• The inhibition of cholesterol ester transfer protein (CETP) by torcetrapib, while raising HDL, did not translate to clinical benefit.

Purpose of the Study:

• To review the potential of short-term infusions of reconstituted HDL or apoA-I as a therapeutic strategy for coronary artery disease.
• To evaluate the viability of HDL/apoA-I infusions based on early clinical trial data.
• To explore alternative approaches to leveraging HDL's protective effects against atherosclerosis.

Main Methods:

• Review of clinical trials evaluating short-term infusions of reconstituted HDL or apoA-I.
• Assessment of cardiovascular imaging technologies and biomarkers used in these trials.
• Analysis of the efficacy and safety data from early-stage development compounds.

Main Results:

• Several HDL and apoA-I infusion compounds have been evaluated in clinical trials.
• Cardiovascular imaging and biomarkers are being utilized to assess potential clinical efficacy.
• Early trial results support the viability of HDL/apoA-I infusion as a therapeutic strategy.

Conclusions:

• Short-term infusions of HDL and/or apoA-I represent a potential therapeutic avenue for treating coronary artery disease.
• This approach circumvents some limitations of oral HDL-raising agents.
• Further development and investigation are warranted based on promising early findings.